TenK10K: Mapping Immune-Cell Genetics Across Disease

ADDED OCTOBER 30, 2026 • RESEARCH EXPLAINER

The central finding

Research described as part of Australia's TenK10K project connects genetic variation with gene activity in specific immune-cell types. The reported work examines more than five million single immune cells from approximately 2,000 people, seeking to explain how disease-associated DNA regions influence cellular behavior.

The research summaries supplied to MKP report associations involving 16 major diseases, nearly 1,500 candidate disease-linked genes, and 893 genes whose genetically influenced activity had not previously been identified. These figures describe research associations, not 1,500 experimentally proven causes of disease.

Why individual immune-cell types matter

Blood contains many kinds of immune cells. An effect detectable in a particular cell subtype can be diluted when all blood cells are analyzed together. Single-cell approaches can identify which cell populations show an association between a DNA variant and a change in gene expression.

Tandem repeats: another layer of regulation

Tandem repeats are stretches of DNA sequence repeated consecutively. They can be challenging to measure and interpret. The supplied summaries describe more than 69,000 repeat variants associated with gene-expression differences, with roughly one-third reportedly specific to a single immune-cell type. They also describe more than 200 candidate therapeutic targets emerging from this line of analysis.

Association with gene expression is not proof that a repeat directly causes disease. Follow-up experiments must distinguish causal effects from nearby linked genetic variation and technical artifacts.

What this could change

Cell-specific genetic maps can help researchers prioritize genes for functional experiments, connect genome-wide association signals to plausible mechanisms, and identify cell populations worth targeting. A treatment that acts on a relevant cell population could someday be more selective—but no new therapy, clinical benefit, or longevity gain follows automatically from a genetic map.

Questions that still need answers

• Which associations replicate in independent and ancestrally diverse cohorts?
• Which candidate genes have direct experimental evidence of a causal role?
• Do the findings hold during infection, inflammation, aging, and other changing immune states?
• Can any proposed target be modulated safely and effectively in patients?

MKP perspective

This is a promising shift from asking only which DNA regions correlate with disease? to asking in which cells might those regions act, and through which regulatory mechanisms? That distinction is important for precision medicine and healthy-aging research, while the distance from discovery to approved treatment remains substantial.

Sources and verification note

This explainer is based on screenshots of a secondary research summary supplied to MKP, which attribute the findings to the Garvan Institute of Medical Research, Murdoch Children's Research Institute, UNSW, and studies in Nature. The exact primary-paper titles, dates, DOIs, and reported counts have not yet been independently checked against the original publications. The figures above should therefore be treated as reported, pending primary-source verification.

• Garvan Institute of Medical Research — research institution; not a direct citation to the specific study.
• Nature — journal portal; exact papers to be linked after verification.

Discuss the evidence

What experiment would most convincingly show that a candidate immune-cell gene actually contributes to disease? How should researchers balance cell-specific targeting with immune-system safety?